Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode: A case report

Pharmacopsychiatry

Volumn 39, Issue 4, 2006, Pages 152-154

  Schonfeldt Lecuona C ^a   Connemann, B J ^a   Wolf, R C ^a   Braun, M ^a   Freudenmann, R W ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; DOXEPIN; LITHIUM; MOCLOBEMIDE; OPIPRAMOL; PAROXETINE; PEMOLINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULPIRIDE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE; VILOXAZINE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CHRONIC FATIGUE SYNDROME; CLINICAL FEATURE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; MAJOR DEPRESSION; NEURASTHENIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REMISSION; SCREENING; SELF MEDICATION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; DEPRESSIVE DISORDER, MAJOR; FATIGUE SYNDROME, CHRONIC; FEMALE; HUMANS; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES;

EID: 33746871099     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-946706     Document Type: Article

References (14)

1. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56: 395-401
2. Bruera E, Driver L, Barnes EA, Willey J, Shen L, Palmer JL et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 2003; 21: 4439-4443
3. Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM et al. ME/CFS: clinical working case definition, diagnostic and treatment protocols. J Chron Fatigue Syndrome 2003; 11: 1-97
4. Cleare AJ, Messa C, Rabiner EA, Grasby PM. Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635. Biol Psychiatry 2005; 57: 239-246
5. Craig T, Kakumanu S. Chronic fatigue syndrome: evaluation and treatment. Am Fam Physician 2002; 65: 1083-1090
6. Cullum JL, Wojciechowski AE, Pelletier G, Simpson JS. Bupropion sustained release treatment reduces fatigue in cancer patients. Can J Psychiatry 2004; 49: 139-144
7. Fishbain DA, Cutler RB, Lewis J, Cole B, Rosomoff HL, Steele-Rosomoff R. Modafinil for the treatment of pain-associated fatigue: review and case report. J Pain Palliat Care Pharmacother 2004; 18: 39-47
8. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994; 121: 953-959
9. Goodnick PJ, Sandoval R. Psychotropic treatment of chronic fatigue syndrome and related disorders. J Clin Psychiatry 1993; 54: 13-20
10. Goodnick PJ, Sandoval R, Brickman A, Klimas NG. Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. Biol Psychiatry 1992; 32: 834-838
11. Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, Straus SE et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988; 108: 387-389
12. Sharpe MC, Archard LC, Banatvala JE, Borysiewicz LK, Clare AW, David A et al. A report-chronic fatigue syndrome: guidelines for research. J R Soc Med 1991; 84: 118-121
13. Steele L, Dobbins JG, Fukuda K, Reyes M, Randall B, Koppelman M et al. The epidemiology of chronic fatigue in San Francisco. Am J Med 1998; 105 (3A): 83S-90S
14. Turkington D, Hedwat D, Rider I, Young AH. Recovery from chronic fatigue syndrome with modafinil. Hum Psychopharmacol 2004; 19: 63-64